Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
about
Impact of soluble epoxide hydrolase and epoxyeicosanoids on human healthSpecific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growthNeoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments.Synergistic tumor suppression by combined inhibition of telomerase and CDKN1ANovel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levelsFrom a multipotent stilbene to soluble epoxide hydrolase inhibitors with antiproliferative properties.Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer.Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivoInhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells.Biological evaluation of a novel sorafenib analogue, t-CUPMGrade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate.Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysisSynergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.A novel p21 attenuator which is structurally related to sorafenib.Role of Mitochondrial DNA Copy Number Alteration in Human Renal Cell Carcinoma.Iron depletion enhances the effect of sorafenib in hepatocarcinomaSynergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMBInhibiting tryptophan metabolism enhances interferon therapy in kidney cancer.Potential biofluid markers and treatment targets for renal cell carcinoma.Less understood issues: p21(Cip1) in mitosis and its therapeutic potential.Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells.Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma.MDM2 Antagonists Counteract Drug-Induced DNA Damage.Aqueous Extracts of Toona sinensis Leaves Inhibit Renal Carcinoma Cell Growth and Migration Through JAK2/stat3, Akt, MEK/ERK, and mTOR/HIF-2α Pathways.16-Hydroxycleroda-3,13-dien-15,16-olide induces anoikis in human renal cell carcinoma cells: involvement of focal adhesion disassembly and signaling
P2860
Q24618018-7016930F-6EDD-4BCB-AC8A-FA45861B9491Q28542417-924EAC3E-75B8-4F02-AF78-C7669F5889A0Q33891216-5F34AE7C-BD93-44DA-B662-47E01C9C5911Q34002435-C7B5A274-1499-4043-9496-129A7C658601Q34627602-7D3165B5-F67A-4E6B-BA15-8414F23C882AQ34675957-8B33BE0E-D8A1-4F24-83A1-656E4241E25DQ34756265-43450556-3B4B-4C68-809D-23821CE9DD31Q34837850-88622348-1E6D-46A1-9ADB-47A262F58247Q34948760-A302AD62-DBDB-4EAE-81FA-4F1FAA1879F9Q35448698-E57E1FDD-7D11-4E69-B60F-FB181E52E760Q35752074-D881C86C-1819-4574-AD25-7946A09A74BDQ36066391-3E1E2E09-75BF-4CFD-870C-4D8B38BE174DQ36101138-0B9DBF39-41ED-4F88-AC80-D4886821408AQ36223025-509EB741-5CE7-4F1D-8E9D-29415E8C0758Q36627593-49C495F4-2D0F-4584-9BD6-641D184DB9ECQ36677729-22C29B24-31CD-402A-B75D-FBC2727ACE36Q37050481-16E42782-5D5C-4211-A267-C0151D4C158CQ37187753-4CAEA1D7-4F51-437B-8ACE-09643C976429Q37613829-3877E374-58FE-472B-A577-111027F6BACBQ37627268-2A35A409-F14E-4CFB-B94C-CFA0C02B23E7Q37687020-3BC26127-5537-4CDC-BBFE-173DEE133739Q38094918-D47AFF8A-12BD-4922-B62A-9E92E5378C4AQ38214413-65AD86EF-EC44-4824-9B54-8569B5E9BB9FQ38260357-344679F8-3CF2-4D26-A4B6-D4E732C8F46CQ38725944-62D8F172-77FC-4DFE-84B8-A6B74ABAFB80Q38759201-45F530CB-117F-489C-9AAA-2DAFAAA219E8Q38763176-41EC679B-B480-460F-8222-1E803D0FD27BQ39256854-A9BBD4F5-1908-404E-9E55-850FED624AA8Q42131424-D9A4061A-C5D0-4A61-876D-C69C9FBC41BAQ42651903-6EBFB872-C05E-4018-81A3-EC17C6988C32Q53114366-0B220C62-F59A-48F6-A738-70CBB43282D9Q59135221-BCE699DA-8F80-4B0D-93C3-B2CB7B169B4B
P2860
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Sorafenib attenuates p21 in ki ...... ith DNA-damaging chemotherapy.
@en
Sorafenib attenuates p21 in ki ...... ith DNA-damaging chemotherapy.
@nl
type
label
Sorafenib attenuates p21 in ki ...... ith DNA-damaging chemotherapy.
@en
Sorafenib attenuates p21 in ki ...... ith DNA-damaging chemotherapy.
@nl
prefLabel
Sorafenib attenuates p21 in ki ...... ith DNA-damaging chemotherapy.
@en
Sorafenib attenuates p21 in ki ...... ith DNA-damaging chemotherapy.
@nl
P2093
P2860
P356
P1476
Sorafenib attenuates p21 in ki ...... ith DNA-damaging chemotherapy.
@en
P2093
Aaron T Wecksler
Bruce D Hammock
Hiromi Inoue
Robert H Weiss
Sung Hee Hwang
P2860
P304
P356
10.4161/CBT.12.9.17680
P577
2011-11-01T00:00:00Z